• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Asthma - Articles and news items

cover

Social media sourced Real World Evidence: A new wave in collecting data

Blog, Z Homepage promo / 3 October 2016 / Peter Brady, CEO Orbital Media and Dr Martin Goldman, independent medical officer, Iatros Consulting

Dr Martin Goldman joins Peter Brady, Orbital Media’s CEO, to discuss how to untap the potential of social media sourced real world evidence…

xolair

FDA approves Xolair to treat allergic asthma in children

Industry news / 11 July 2016 / Victoria White, Digital Content Producer

The FDA has approved Genentech’s Xolair (omalizumab) to treat moderate to severe persistent asthma in children six to 11 years of age…

Tiotropium found to improve lung function of children with asthma

Tiotropium found to improve lung function of children with asthma

Industry news / 18 May 2016 / Katie Sadler

New data has revealed tiotropium improves lung function in children who continue to experience asthma symptoms despite taking other maintenance therapies.

Advair Diskus

GSK’s Advair Diskus achieves primary endpoint in LABA safety study

Industry news / 17 March 2016 / Victoria White

The VESTRI study compared Advair Diskus to fluticasone propionate monotherapy in children aged 4 – 11 years who have asthma…

RPL554

Verona Pharma announces positive headline data from RPL554 trial

Industry news / 15 March 2016 / Victoria White

The study met its primary objective, with nebulised RPL554 demonstrating a dose-dependent bronchodilator response in asthma patients…

eosinophil levels

GSK presents data on of Nucala in asthma patients stratified by eosinophil levels

Industry news / 9 March 2016 / Victoria White

The post-hoc analysis confirms the predictive nature of the relationship between baseline blood eosinophil counts and efficacy outcomes in patients treated with mepolizumab…

Spiriva Respimat

Spiriva Respimat effective regardless of allergy subtype, study finds

Industry news / 8 March 2016 / Victoria White

The addition of Spiriva Respimat to other asthma maintenance therapies helps improve asthma symptom control regardless of allergy subtype…

BI 655066

AbbVie and Boehringer Ingelheim collaborate on BI 655066

Industry news / 7 March 2016 / Victoria White

BI 655066 is an anti-IL-23 monoclonal biologic antibody being evaluated in psoriasis, Crohn’s disease, psoriatic arthritis and asthma…

lebrikizumab

Roche provides update on two Phase III studies of lebrikizumab in asthma

Industry news / 29 February 2016 / Victoria White

LAVOLTA I and II are two identical, randomised, multicentre, placebo-controlled Phase III studies designed to evaluate the efficacy and safety of lebrikizumab…

Spiriva Respimat

Boehringer Ingelheim’s Spiriva Respimat available in the US

Industry news / 4 February 2016 / Victoria White

Unlike other asthma daily maintenance treatments, Spiriva Respimat is from a new class of medications in asthma known as long-acting anticholinergics…

RPL554

Do asthma and COPD exist? Experts call for a new approach to patient management

Industry news / 1 February 2016 / Victoria White

Defining a patient’s symptoms using the historical diagnostic labels of asthma and COPD is an outdated approach, according to experts…

mepolizumab

CHMP recommends mepolizumab for severe refractory eosinophilic asthma

Industry news / 24 September 2015 / Victoria White

Mepolizumab is an anti-IL 5 monoclonal antibody that is delivered in a 100mg dose via subcutaneous injection every four weeks…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +